Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Recurrence × Topotecan × Clear all

Phase

Status

Completed 8 Terminated 6 Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Small Cell Lung Carcinoma 6 Neuroblastoma 6 Rhabdoid Tumor 2 Ovarian Neoplasms 2 Neoplasms 2 Neoplasm Metastasis 2 Fallopian Tube Neoplasms 2 Thrombocythemia, Essential 1 Sarcoma, Ewing 1 Sarcoma 1 Rhabdomyosarcoma 1 Retinoblastoma 1 Recurrence 1 Primary Myelofibrosis 1 Polycythemia Vera 1 Pancreatic Neoplasms 1 Myelodysplastic-Myeloproliferative Diseases 1 Medulloblastoma 1 Lung Neoplasms 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1 Leukemia, Myeloid, Acute 1 Ganglioneuroblastoma 1 Epilepsy 1 Diffuse Intrinsic Pontine Glioma 1 Carcinoma, Neuroendocrine 1 Bone Neoplasms 1

Interventions

Cyclophosphamide 18 Dexamethasone 17 fludarabine 11 pomalidomide 8 carfilzomib 7 Rituximab 7 pembrolizumab 6 fludarabine phosphate 6 daratumumab 6 Lenalidomide 6 Calcium Dobesilate 6 venetoclax 5 Gemcitabine 5 Cisplatin 5 Bortezomib 5 Nivolumab 4 Etoposide 4 isatuximab 3 elotuzumab 3 Vincristine 3 Prednisone 3 Ipilimumab 3 Injections 3 Doxorubicin 3 Carboplatin 3 tisagenlecleucel 2 ruxolitinib 2 obinutuzumab 2 dexamethasone 21-phosphate 2 cemiplimab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02298348 2025-02-17

N2013-02

New Approaches to Neuroblastoma Therapy Consortium

Phase 1 Active not recruiting

Neuroblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡